← Eichor
Study identifier: NCT05978505 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Reboxetine for Sleep Apnoea After ENT Surgery

Condition: Sleep Apnea, Obstructive  ·  Sponsor: Flinders University

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.

This description comes directly from the study's public registry record.

Talk to the study team

Emma Thomas  ·  +61882012912  ·  ethomas@flinders.edu.au

Carolin Tran  ·  +61874219873  ·  carolin.tran@flinders.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

Flinders, Private and Public Hospitals and Flinders UniversityBedford Park, South Australia, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05978505